Marine-derived pharmaceuticals have been used as sources of providing a range of chemical diversity in drug discovery. Marine-derived pharmaceuticals are the outcome of a breakthrough application of biotechnology. They enable producing therapeutic agents that could ultimately be used by the medical community to combat life-threatening illnesses. The sudden increase in the utilization of marine-derived pharmaceutical products can be directly linked to the uptake of research activities in this space. These marine derived pharmaceutical products require a significant amount of basic and applied research, so that they can be compared in terms of efficacy and safety and quality to patented pharmaceutical products that are in the market.
The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.
The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Keywords: Marine-derived pharmaceuticals, chemical diversity, marine biotechnology, pharmaceutical potential, marine organism